Structural and Functional Roles of the Membrane-Related Components of Single-Pass Membrane Proteins
单程膜蛋白膜相关成分的结构和功能作用
基本信息
- 批准号:10380877
- 负责人:
- 金额:$ 44.2万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-05-01 至 2023-01-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
PROJECT SUMMARY
My laboratory investigates the structural and functional roles of the transmembrane (TM) and membrane-
proximal (MP) regions of immune receptors and viral fusion proteins. The single-pass transmembrane (TM)
proteins account for the vast majority of signaling receptors on the cell surface, and due to the lack of structural
information, the TM/MP regions are often the missing link in our understanding of how extracellular ligand binding
is translated to the activation of intracellular signaling pathways. TM and MP regions of single-pass membrane
proteins are extremely difficult to visualize. We have developed an effective NMR/biochemistry technology
platform for visualizing these regions and found that they can have surprisingly important biological function other
than membrane anchoring. We find that a few receptors in the tumor necrosis factor receptor superfamily
(TNFRSF) exhibit a previously unknown phenomenon that their transmembrane domains (TMDs) alone can
oligomerize in membrane and drive receptor clustering and activation. In another finding, the TM region of the
HIV-1 envelope spike form defined trimeric structure that can strongly influence the antigenicity of the
ectodomain of the spike currently being used for vaccine development. The above few examples already suggest
the enormous potential of uncovering the membrane regions of type I/II membrane proteins in discovering new
biological mechanisms, which is the motivation for the proposed research. In the next five years, we will continue
to explore the structure and function of TM regions with three specific goals. (1) We will further examine the
mechanism of TMD-mediated receptor clustering and activation for other members of the TNFRSF and test the
generality of this new concept in receptor biology. (2) We will explore the function of TMD oligomerization in the
signaling mechanism of the chain cytokine receptors, for which the membrane regions are completely unknown.
(3) We will continue to examine the TM and MP regions of other viral fusion proteins such as that of SIV and
coronavirus, for understanding how the membrane-interacting components of the fusion proteins stabilize the
prefusion state of the envelope spikes and for revealing unique structural features that may be used for testing
mechanistic hypotheses of viral membrane fusion.
项目摘要
我的实验室研究了跨膜(TM)和膜的结构和功能作用
免疫受体和病毒融合蛋白的近端(MP)区域。单通跨膜(TM)
蛋白质占细胞表面上绝大多数信号接收器的解释,并且由于缺乏结构
信息,TM/MP区域通常是我们对细胞外配体结合的理解中缺少的联系
被翻译成细胞内信号通路的激活。单通膜的TM和MP区域
蛋白质极难可视化。我们已经开发了有效的NMR/生物化学技术
可视化这些区域的平台,发现它们可以具有令人惊讶的重要生物学功能
比膜锚定。我们发现肿瘤坏死因子受体超家族中的一些受体
(TNFRSF)暴露了以前未知的现象,即它们的跨膜结构域(TMD)可以
在膜上寡聚,并驱动受体聚类和激活。在另一个发现中,
HIV-1包膜尖峰形式定义了三聚体结构,可以强烈影响
目前用于疫苗开发的尖峰的外体域。以上几个例子已经暗示
发现新的I/II膜蛋白的膜区域的巨大潜力
生物学机制,这是拟议研究的动机。在接下来的五年中,我们将继续
探索具有三个特定目标的TM区域的结构和功能。 (1)我们将进一步研究
TMD介导的受体聚类和激活的机制,用于TNFRSF的其他成员并测试
这种新概念在受体生物学中的普遍性。 (2)我们将探讨TMD寡聚的功能
链细胞因子受体的信号传导机制,膜区域完全未知。
(3)我们将继续研究其他病毒融合蛋白的TM和MP区域,例如SIV和SIV和MP
冠状病毒,以了解融合蛋白的膜相互作用成分如何稳定
信封尖峰的预选状态,并揭示可用于测试的独特结构特征
病毒膜融合的机械假设。
项目成果
期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
A trimeric hydrophobic zipper mediates the intramembrane assembly of SARS-CoV-2 spike.
三聚体疏水拉链介导 SARS-CoV-2 刺突的膜内组装。
- DOI:10.1101/2021.04.09.439203
- 发表时间:2021
- 期刊:
- 影响因子:0
- 作者:Fu,Qingshan;Chou,JamesJ
- 通讯作者:Chou,JamesJ
共 1 条
- 1
JAMES Jeiwen CHOU的其他基金
CONTROL AND ACTIVATION OF THE TUMOR NECROSIS FACTOR RECEPTORS
肿瘤坏死因子受体的控制和激活
- 批准号:1033810610338106
- 财政年份:2020
- 资助金额:$ 44.2万$ 44.2万
- 项目类别:
CONTROL AND ACTIVATION OF THE TUMOR NECROSIS FACTOR RECEPTORS
肿瘤坏死因子受体的控制和激活
- 批准号:1009295110092951
- 财政年份:2020
- 资助金额:$ 44.2万$ 44.2万
- 项目类别:
Structure-function studies of the membrane-interacting domains of HIV-1 Env spike
HIV-1 Env 刺突膜相互作用域的结构功能研究
- 批准号:1032663210326632
- 财政年份:2016
- 资助金额:$ 44.2万$ 44.2万
- 项目类别:
Structure-function studies of the membrane-interacting domains of HIV-1 Env spike
HIV-1 Env 刺突膜相互作用域的结构功能研究
- 批准号:92032149203214
- 财政年份:2016
- 资助金额:$ 44.2万$ 44.2万
- 项目类别:
Structure-function studies of the membrane-interacting domains of HIV-1 Env spike
HIV-1 Env 刺突膜相互作用域的结构功能研究
- 批准号:92759219275921
- 财政年份:2016
- 资助金额:$ 44.2万$ 44.2万
- 项目类别:
Structure-function studies of the membrane-interacting domains of HIV-1 Env spike
HIV-1 Env 刺突膜相互作用域的结构功能研究
- 批准号:98991719899171
- 财政年份:2016
- 资助金额:$ 44.2万$ 44.2万
- 项目类别:
Function and mechanism of the HCV p7 channel and its therapeutic potential
HCV p7通道的功能、机制及其治疗潜力
- 批准号:91980399198039
- 财政年份:2016
- 资助金额:$ 44.2万$ 44.2万
- 项目类别:
Function and mechanism of the HCV p7 channel and its therapeutic potential
HCV p7通道的功能、机制及其治疗潜力
- 批准号:88804438880443
- 财政年份:2014
- 资助金额:$ 44.2万$ 44.2万
- 项目类别:
Membrane protein structures by solution NMR
通过溶液 NMR 确定膜蛋白结构
- 批准号:81404708140470
- 财政年份:2010
- 资助金额:$ 44.2万$ 44.2万
- 项目类别:
相似国自然基金
非洲猪瘟病毒B475L蛋白靶向LMP2抑制抗原递呈的分子机制
- 批准号:32302894
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于HBV和肝癌相关抗原免疫优势T细胞表位的双靶人工抗原提呈细胞治疗HBV相关肝癌的研究
- 批准号:82303729
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
KIF17介导肿瘤细胞MHC-II胞膜定位促进乳腺癌抗原提呈及免疫应答的机制研究
- 批准号:82372781
- 批准年份:2023
- 资助金额:46 万元
- 项目类别:面上项目
微量肝癌组织肿瘤新抗原高效稳定深度覆盖鉴定技术研究
- 批准号:32371503
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
钩吻素子对胃癌MHC-I类抗原呈递激活免疫应答的调控及其机制研究
- 批准号:82373138
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
相似海外基金
Formulation of a prophylactic vaccine against Pseudomonas aeruginosa
铜绿假单胞菌预防性疫苗的配制
- 批准号:1059237410592374
- 财政年份:2022
- 资助金额:$ 44.2万$ 44.2万
- 项目类别:
Regulation of Proinflammatory Cytokine Responses by a Caspase-8-N4BP1 Axis
Caspase-8-N4BP1 轴对促炎细胞因子反应的调节
- 批准号:1070406510704065
- 财政年份:2022
- 资助金额:$ 44.2万$ 44.2万
- 项目类别:
Formulation of a prophylactic vaccine against Pseudomonas aeruginosa
铜绿假单胞菌预防性疫苗的配制
- 批准号:1048140910481409
- 财政年份:2022
- 资助金额:$ 44.2万$ 44.2万
- 项目类别:
Discovery of diverse nucleotide immune signals for use as novel immunotherapies
发现多种核苷酸免疫信号用作新型免疫疗法
- 批准号:1052857910528579
- 财政年份:2022
- 资助金额:$ 44.2万$ 44.2万
- 项目类别:
Restoring age-dependent vaccine unresponsiveness by a novel ASP-1 adjuvant combination
通过新型 ASP-1 佐剂组合恢复年龄依赖性疫苗无反应
- 批准号:1045855310458553
- 财政年份:2021
- 资助金额:$ 44.2万$ 44.2万
- 项目类别: